The global botanical and plant-derived drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Botanical drugs are made from plants that have therapeutic properties. Algae and vegetable components, as well as microscopic fungus, are found in botanical drugs. Botanical and plant-derived drugs are used to treat a variety of conditions, including CNS disorders, infectious diseases, CVD, and respiratory diseases. Botanical drugs come in a variety of formats, including pills, tablets, and injections. 

Botanical drugs are widely employed for a variety of purposes. The rising prevalence of skin problems is a major factor driving the increased use of botanical drugs in dermatology. Several central nervous system receptors can interact with plant extracts and components to impact pharmacology, making them relevant in the treatment of diseases including central nerve disorders. Hormone illnesses are largely endocrine system diseases that affect the glands of the endocrine system directly. Other disorders with therapeutic applicability include respiratory diseases, joint diseases, and kidney diseases.

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including product launches, partnerships and collaborations, mergers and acquisitions, geographical expansion to remain competitive in the marketplace. For instance, in November 2021, NFL Biosciences SA, a biopharmaceutical company engaged in the development of botanical drugs for the treatment of addictions, and Diverchim, a French company engaged in the GMP development and production of novel molecules, are announcing that they have set up a partnership. Diverchim will manage the production of liquid protein extracts from tobacco and cannabis leaves, which are the core components of NFL-101, NFL Biosciences’ botanical drug candidate for the treatment of tobacco addiction, and NFL-201, for treating cannabis dependence. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Source

o By Dosage Form

o By Therapeutic Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Bayer Healthcare, LLC, GlaxoSmithKline plc, and GW Pharmaceuticals, plc, among others

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Botanical and Plant-Derived Drugs Market Report by Segment

By Source

• Plant
• Algae
• Macroscopic Fungi
• Others

By Dosage Form

• Pills
• Tablets
• Capsules
• Others

By Therapeutic Application 

• CVD
• Infectious Diseases
• Dermatology
• Central Nervous System
• Respiratory Diseases
• Others

Global Botanical and Plant-Derived Drugs Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa